G protein-coupled receptors: Bridging the gap from the extracellular signals to the Hippo pathway

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 1, 2014, Pages 10-15

  Zhou, Xin ^a,b   Wang, Zhen ^a,c,d   Huang, Wei ^a,e   Lei, Qun Ying ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FUDAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

cancer; G proteins; GPCR; Hippo; TAZ; YAP

Indexed keywords

CYTOSKELETON PROTEIN; G PROTEIN COUPLED RECEPTOR; HIPPO PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ANIMAL; BIOLOGICAL MODEL; CARCINOGENESIS; CELL PROLIFERATION; CYTOSKELETON; HOMEOSTASIS; HUMAN; METABOLISM; ORGAN SIZE; OXIDATIVE STRESS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CYTOSKELETAL PROTEINS; CYTOSKELETON; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; ORGAN SIZE; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84922475217     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu108     Document Type: Review

References (63)

1. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010, 19: 491-505.
2. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013, 13: 246-257.
3. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev 2010, 24: 862-874.
4. Yu FX, Guan KL. The Hippo pathway: Regulators and regulations. Genes Dev 2013, 27: 355-371.
5. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the Hippo pathway. Mol Cell Biol 2008, 28: 2426-2436.
6. Zhao B,Wei X, LiW, Udan RS, Yang Q, Kim J, Xie J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007, 21: 2747-2761.
7. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, et al. Elucidation of a universal size-control mechanism in Drosophila and mammal s. Cell 2007, 130: 1120-1133.
8. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008, 283: 5496-5509.
9. Zhao B, Li L, Tumaneng K,Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev 2010, 24: 72-85.
10. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, et al. The Hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem 2010, 285: 37159-37169.
11. Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y, Xiong Y, et al. The N-terminal phosphodegron t argets TAZ/WWTR1 protein for SCFbeta-TrCP-dependent degradation in response to phosphatidylinositol-3-kinase inhibition. J Biol Chem 2012, 287: 26245-26253.
12. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, et al. TEAD mediates YAPdependent gene induction and growth control. Genes Dev 2008, 22: 1962-1971.
13. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009, 284: 13355-13362.
14. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007, 17: 2054-2060.
15. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011, 144: 782-795.
16. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125: 1253-1267.
17. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, HunzikerW, Zeng Q, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008, 68: 2592-2598.
18. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147: 759-7 72.
19. Grusche FA, RichardsonHE, Harvey KF. Upstream regulation of the Hippo size control pathway. Curr Biol 2010, 20: R574-R582.
20. Zhao B Tumaneng K Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal Nat Cell Biol 2011 13 877-883.
21. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474: 179-183.
22. Zhao B, Li L,Wang L,Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012, 26: 54-68.
23. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010, 19: 27-38.
24. Dai X, She P, Chi F, Feng Y, Liu H, Jin D, Zhao Y, et al. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem 2013, 288: 34041-34051.
25. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011, 25: 51-63.
26. Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, Sun Y, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kin ases. Proc Natl Acad Sci USA 2013, 110: 17368-17373.
27. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, Persson NL, et al. A tight junction-associated Merl in-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011, 19: 527-540.
28. Wang W, Huang J, Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem 2011, 286: 4364-4370.
29. Xiao L, Chen Y, Ji M, Dong J. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem 2011, 286: 7788-7796.
30. Moleirinho S, Chang N, Sims AH, Tilston-Lunel AM, Angus L, Steele A, Boswell V, et al. KIBRA exhibits MST-independent functional reg ulation of the Hippo signaling pathway in mammals. Oncogene 2013, 32: 1821-1830.
31. Das Thakur M, Feng Y, Jagannathan R, Seppa MJ, Skeath JB, Longmore GD. Ajuba LIM proteins are neg ative regulators of the Hippo signaling pathway. Curr Biol 2010, 20: 657-662.
32. Habbig S, Bartram MP, Muller RU, Schwarz R, Andriopoulos N, Chen S, Sagmuller JG, et al. NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol 2011, 193: 633-642.
33. Nguyen HB, Babcock JT, Wells CD, Quilliam LA. LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. Oncogene 2013, 32: 4100-4109.
34. Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D, Bader GD, et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and s ignalling. Biochem J 2010, 432: 461-472.
35. WangW, Huang J,Wang X, Yuan J, Li X, Feng L, Park JI, et al. PTPN14 is required for the density-dependent control of YAP1. Genes Dev 2012, 26: 1959-1971.
36. Miller E, Yang J, DeRan M, Wu C, Su AI, Bonamy GM, Liu J, et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP . Chem Biol 2012, 19: 955-962.
37. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signa ling. Cell 2012, 150: 780-791.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011, 144: 646-674.
39. Cai H, Xu Y. The r ole of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 2013, 11: 31.
40. Jeong GO, Shin SH, Seo EJ, Kwon YW, Heo SC, Kim KH, Yoon MS, et al. TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. Cell Physiol Biochem 2013, 32: 253-263.
41. Mo JS Yu FX Gong R Brown JH Guan KL. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs) Genes Dev 2012 26 2138-2143.
42. Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, Henklein P, et al. Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol 2007, 211: 699-707.
43. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007, 7: 79-94.
44. Rossman KL, Der CJ, Sondek J. GEF means go: Turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005, 6: 167-180.
45. Sah VP, Seasholtz TM, Sagi SA, Brown JH. The role of Rho in G proteincoupled receptor signal transduction. Annu Rev Pharmacol Toxicol 2000, 40: 459-489.
46. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev 2005, 85: 1159-1204.
47. Bao Y, Nakagawa K, Yang Z, Ikeda M, Withanage K, Ishigami-Yuasa M, Okuno Y, et al. A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dep endent gene transcription. J Biochem 2011, 150: 199-208.
48. Yu FX, Zhang Y, ParkHW, Jewell JL, Chen Q, Deng Y, Pan D, et al. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev 2013, 27: 1223-1232.
49. Kim M, Kim M, Lee S, Kuninaka S, Saya H, Lee H, Lee S, et al. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. EMBO J 2013, 32: 1543-1555.
50. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: New approaches to therapy. Cancer Res 1990, 50: 7093-7100.
51. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363: 2191-2199.
52. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457: 599-602.
53. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, et al. Mutant Gq/11 promot e uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25: 822-830.
54. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 2014, 25: 831-845.
55. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012, 26: 1300-1305.
56. Sudol M, Shields DC, Farooq A. Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin Cell Dev Biol 2012, 23: 827-833.
57. Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014, 25: 166-180.
58. Sorrentino G, Rugger i N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014, 16: 357-366.
59. Eberlein M, He usinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001, 133: 1172-1180.
60. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 2013, 13: 412-424.
61. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Group AS, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011, 30: 281 0-2822.
62. Yeo MK, Kim SH, Kim JM, Huang SM, Kim MR, Song KS, Kim KH. Correlation of expression of phosphorylated and non-phosphorylated Yesassociated protein with clinicopathological parameters in esoph ageal squamous cell carcinoma in a Korean population. Anticancer Res 2012, 32: 3835-3840.
63. Steinhardt AA Gayyed MF Klein AP Dong J Maitra A Pan D Montgomery EA et al. E xpression of Yes-associated protein in common solid tumors Hum Pathol 2008 39 1582-1589.